hrp0082fc2.6 | Bone & Mineral | ESPE2014

Efficacy and Safety Following 4 Monthly s.c. Doses of a Human Anti-Fibroblast Growth Factor 23 Antibody (KRN23) in Adults with X-linked Hypophosphatemia

Peacock Munro , Imel Erik , Zhang Xiaoping , Ruppe Mary , Weber Thomas , Klausner Mark , Ito Takahiro , Vergeire Maria , Humphrey Jeffrey , Glorieux Francis , Portale Anthony , Insogna Karl , Carpenter Thomas

Background: In X-linked Hypophosphatemia (XLH), abnormally elevated serum Fibroblast Growth Factor 23 (FGF23) results in low renal maximum threshold for phosphate reabsorption (TmP/GFR), low serum phosphorus (Pi), inappropriately normal 1,25-dihydroxyvitamin D (1,25(OH)2D) and development of rachitic deformities.Methods: Up to four SC KRN23 doses were given every 28 days to 28 adults with XLH (26 completed) according to a dose-escalation algorithm (0.05&...

hrp0082p1-d2-35 | Bone | ESPE2014

Assessment of Quality of Life Data After 4 Monthly S.C. Doses of a Human Monoclonal Anti-Fibroblast Growth Factor 23 Antibody (KRN23) in Adults with X-linked Hypophosphatemia

Ruppe Mary , Zhang Xiaoping , Imel Erik , Weber Thomas , Klausner Mark , Ito Takahiro , Vergeire Maria , Humphrey Jeffrey , Glorieux Francis , Portale Anthony , Insogna Karl , Peacock Munro , Carpenter Thomas

Objectives: In X-linked hypophosphatemia (XLH), abnormally elevated serum Fibroblast growth Factor 23 (FGF23) results in low renal maximum threshold for phosphate reabsorption, low serum phosphorus, inappropriately normal 1,25-dihydroxyvitamin D, and development of rachitic deformities. The effect of KRN23 on health-related quality of life (HRQL) was assessed.Methods: Open-label KRN23 was given s.c. every 28 days up to four doses to 28 adults with XLH (2...

hrp0082p2-d1-365 | Fat Metabolism & Obesity | ESPE2014

Large-Born Infants Switch from an Adipose to a Lean and Insulin-Sensitive State with Low Concentrations of Circulating Myostatin and Follistatin

Sebastiani Giorgia , Cruz Miriam Perez , Silva Marta Diaz , Roig Maria Dolores Gomez , Bermejo Abel Lopez , Toda Lourdes Ibanez , De Zegher Francis

Background: Muscle is key to glucose metabolism. Myogenesis is completed in early infancy, partly under the inhibitory control of myostatin, a myokine whose actions can be influenced by follistatin. Early lowering of myostatin actions is thus a potential strategy to reduce the risk for later diabetes.Objective and hypotheses: We performed a first screening of whether such lowering is among the natural mechanisms whereby some human infants augment their l...

hrp0082p2-d1-366 | Fat Metabolism & Obesity | ESPE2014

Uric Acid and Risk for Atherosclerotic Disease Early in Life

Bassols Judit , Martinez-Calcerrada Jose-Maria , Prats-Puig Anna , Carreras-Badosa Gemma , Diaz-Roldan Ferran , Osiniri Ines , Riera-Perez Elena , de Zegher Francis , Ibanez Lourdes , Lopez-Bermejo Abel

Background: Increased uric acid is an independent risk factor for cardiovascular disease in obese adults and adolescents. The relationship between uric acid and atherosclerotic risk early in life is unknown.Objective and hypotheses: We investigated whether uric acid relates to carotid intima–media thickness (cIMT), a marker of preclinical atherosclerosis, in a rather large sample of school-age children and investigated the interaction of obesity sta...

hrp0084fc8.1 | Obesity - Basic | ESPE2015

DLK1 Expression in Adipose Tissue Following Fetal Growth Restriction: Relation to Visceral Fat Expansion and Catch-Up Growth in Wistar Rats

Carreras-Badosa Gemma , Remesar Xavier , Prats-Puig Anna , Diaz-Roldan Ferran , Platero-Gutierrez Estibaliz , Martinez-Calcerrada Jose-Maria , de Zegher Francis , Ibanez Lourdes , Bassols Judit , Lopez-Bermejo Abel

Background: DLK1 (PREF1) is a key inhibitor of adipogenesis and adipocyte differentiation. Adipose tissue expansion depends on adequate adipocyte differentiation. However, whether lower DLK1 expression facilitates adipose tissue expansion following fetal growth restriction is so far unknown.Objective and hypotheses: To study the expression of DLK1 in the adipose tissue of prenatally growth-restricted rats and its relat...

hrp0094p2-237 | Fetal, neonatal endocrinology and metabolism (to include hypoglycaemia) | ESPE2021

Placenta n-6/n-3 PUFA ratio is associated with visceral adiposity and cardiovascular risk in the offspring at 6 years of age

Gomez-Vilarrubla Ariadna , Mas-Pares Berta , Carreras-Badosa Gemma , Bonmati Alexandra , Martinez-Calcerrada Jose-Maria , Puerto-Carranza Elsa , de Zegher Francis , Ibanez Lourdes , Lopez-Bermejo Abel , Bassols Judit ,

Background and Aims: Long chain polyunsaturated fatty acids (LC-PUFA) are essential nutrients for the development of the fetus and are supplied by the mother through the placenta. Omega-6 arachidonic acid (AA) and both omega-3 eicosapentaenoic acid (EPA) and docoshexaenoic acid (DHA) stand out for their functional roles. Recent studies show that the concentrations of these fatty acids in maternal blood and umbilical cord are associated with adiposity in the of...

hrp0094p2-330 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Short stature and efficacy of growth hormone treatment in a child with Nail-Patella Syndrome. A case report.

Pankratova Maria , Kareva Maria ,

Background: Nail-Patella syndrome (NPS) or hereditary onycho-osteodysplasia (OMIM: 161200) is an autosomal dominant disorder characterized by nail and elbow dysplasia, patellar aplasia or hypoplasia, nephropathy and intra-ocular hypertension. The diagnosis confirmes by pathogenic variant in the LMX1B gene. There are reports of short stature in patients with this syndrome, however, data of the use of somatropin have not been presented. We describe the ...

hrp0084p2-500 | Perinatal | ESPE2015

Birth Incidence of Prader-Willi Syndrome in France

Bar Celine , Diene Gwenaelle , Molinas Catherine , Casper Charlotte , Tauber Maithe

Background: Prader-Willi syndrome (PWS) is a rare and complex genetic disorder characterised in neonates by hypotonia and feeding problems. French birth incidence has never been reported.Objective and hypotheses: To evaluate incidence of PWS at birth in France.Method: Identification of patients with a molecular diagnosis of PWS born between January 1st, 2013 and December 31st, 2013 was obtained by combining va...

hrp0092fc4.4 | Fat Metabolism and Obesity Session | ESPE2019

The rs72613567:TA Variant in the Hydroxysteroid 17-beta Dehydrogenase 13 Gene Reduces Liver Damage in Obese Children

Sessa Anna Di , Rosaria Giuseppina , Cirillo Grazia , Marzuillo Pierluigi , Arienzo Maria Rosaria , Pedulla' Marcella , Miraglia Del Giudice Emanuele

Background: The rs72613567:TA variant in the hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) gene has been associated with decreased risk of liver damage.Aims: To investigate the association between the HSD17B13 rs72613567:TA variant and both hepatic steatosis and biochemical markers of liver damage in obese children and to evaluate its potential effect in NAFLD genetic predisposition.<p...

hrp0089p1-p073 | Diabetes &amp; Insulin P1 | ESPE2018

Efficacy of Real-time Continuous Glucose Monitoring in Type 1 Diabetic Pre-school and School Children Treated with Multiple Daily Injections

Schiaffini Riccardo , Rapini Novella , Pellicano Grazia , Patera Patrizia Ippolita , Ciampalini Paolo , Matteoli Maria Cristina , Deodati Annalisa , Cianfarani Stefano

Background: Young children affected by Type 1 Diabetes (T1D) are prone to glucose fluctuations and hardly reach a stable glycometabolic control, especially when treated with a Multiple Daily Insulin Injections (MDI) scheme. The recent Real-Time Continuous Glucose Monitoring (RT-CGM) System, Dexcom G5, the only available device registered for non-adjunctive insulin intervention, potentially facilitates a better management of the disease. Evidence regarding CGM effectiveness amo...